Phaseline

Targets › SFLT1

SFLT1: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Ophthalmology; next expected readout Mar 2029.

Open in Phaseline: the race on SFLT1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Oxford BioMedicaRetinoStat
Adeno-associated virus (AAV) vector delivering soluble fms-like tyrosine kinase-1 (sFLT1)
SFLT1Phase 1Age-Related Macular DegenerationMar 2029

Conditions

Age-Related Macular Degeneration (1)

Modalities

small molecule (1)

Companies

Oxford BioMedica (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.